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Abstract
Background: The regulatory mechanisms of the expression of connective tissue growth factor/CCN family member
2 (CTGF/CCN2) in human articular chondrocytes have not been clarified. We investigated the effect of
prostaglandin E2 (PGE2) on CTGF/CCN2 expression in chondrocytes.
Findings: Articular cartilage samples were obtained from patients with osteoarthritis (OA) and chondrocytes were
isolated and cultured in vitro. Chondrocytes were stimulated with PGE2, PGE receptor (EP)-specific agonists, or
interleukin (IL)-1. CTGF expression was analyzed using quantitative polymerase chain reaction, Western blot, and
enzyme-linked immunosorbent assay. The inhibitory effects of EP receptor antagonists (for EP2 and EP4) against
PGE2 stimulation were also investigated. Stimulation of chondrocytes with PGE2 or IL-1 significantly suppressed
CTGF expression. The suppressive effect of PGE2 was reproduced by EP2/EP4 receptor agonists but not by EP1/EP3
receptor agonists, and was partially blocked by an EP4 receptor antagonist, suggesting that the EP4 receptor has a
dominant role.
Conclusions: PGE2 may be involved in the regulation of CTGF/CCN2 expression in human articular chondrocytes
via the EP4 receptor. Elucidation of EP4-mediated signaling in chondrocytes may contribute to a better
understanding of the effects of PGE2 in arthritis.
Background
Connective tissue growth factor/CCN family member 2
(CTGF/CCN2) is a member of the CCN family, which is
a group of secreted multifunctional proteins that contain
high levels of cysteine (reviewed in [1]). During skeletal
development, CTGF is strongly expressed in the
mesenchyme, including in hypertrophic chondrocytes,
and plays an essential role in endochondral ossification
by promoting angiogenesis, proliferation, and differentia-
tion of chondrocytes [2]. In adult tissue, CTGF is
expressed during wound healing and in fibrotic tissue
[2,3]. Transforming growth factor (TGF)-b stimulates
CTGF expression, and TGF-b-induced CTGF is involved
in scarring and fibrogenesis [3]. In chondrocytes, CTGF
contributes to the production of the extracellular matrix
by stimulating chondrocyte proliferation, the expression
of type II collagen, and aggrecan among other factors,
and the activation of integrin signaling [4,5]. CTGF
expression is detected in normal human cartilage and in
cartilage from patients with osteoarthritis (OA), suggest-
ing that CTGF expression is involved in the develop-
ment of fibrous tissue over the damaged OA cartilage
[6,7].
Despite its potential involvement in OA, the regula-
tory mechanisms of CTGF expression in chondrocytes
have not been fully clarified. Studies using chondrocytic
cells and other cell types indicate that CTGF expression
is modulated by several factors, including TGF-b [8],
dexamethasone[9], and macrophage colony stimulating
factor [10]. A regulatory role of prostaglandin E2 (PGE2)
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PGE2 is considered an important catabolic factor in OA
cartilage [13]; therefore, the present study aimed to eval-
uate the potential contribution of PGE2 in the regulation
of CTGF expression in OA chondrocytes.
Methods
Samples
Human articular chondrocytes were obtained from 17
patients (M/F = 2:15, mean age 74.2 ± 5.38) with OA
who underwent arthroplasty of a knee (15) or hip (2)
joint at St. Marianna University School of Medicine
Hospital. The diagnoses of OA was made according to
the criteria of the American College of Rheumatology
[14]. Written informed consent was obtained from each
patient, and the study protocol was approved by the
institution’s ethics committee. The study was performed
in compliance with the tenets of the Declaration of Hel-
sinki proposed by the World Medical Association in
1964.
Cell culture
After careful removal of the synovial tissue, the cartilage
was minced, washed, and treated with collagenase. Iso-
lated chondrocytes were then washed and cultured in
vitro as a monolayer in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and
antibiotics. The fetal bovine serum used in the study
was inactivated by incubation at 56°C for 30 min. The
attached cells (P0) were grown on type I collagen-coated
culture dishes, and subconfluent cells (P1 cells) were
used in the experiments. The differentiated phenotypes
of the cells used in the experiments were confirmed
through macroscopic observation and on the basis of
the expression of type II collagen and aggrecan mRNA
by reverse transcription-polymerase chain reaction
(PCR; data not shown).
Chondrocytes were serum-starved in medium with
0.5% fetal bovine serum for 24 h prior to the experi-
ments and were either stimulated or not stimulated with
PGE2 (10 nM; Cayman Chemical Co., Ann Arbor, MI),
butaprost (10 μM, Sigma-Aldrich, St. Louis, MO), PGE1
alcohol (10 nM), sulprostone (1 μM, Sigma-Aldrich), or
IL-1b (10 ng/ml, R&D Systems, Minneapolis, MN), for
the indicated periods. In a separate experiment, cells
were pretreated with either AH6809 (10 ng/ml) or
GW627368X (5 μM; Cayman Chemical Co., Ann Arbor,
MI) for 1 h before stimulation with PGE2. Cell viability
was not affected by up to 500 nM PGE2, the vehicle, or
any of the inhibitors during the culture period, as con-
firmed by trypan blue exclusion and an MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)- 2H-tetrazolium] assay (data not shown).
Stimulated chondrocytes and culture supernatants were
collected and subjected to the following analyses.
Real-time PCR
Messenger RNA was extracted from the cultured cells
and converted to cDNA. Quantitative PCR was per-
formed using specific primers and an ABP Prism 7000
according to the manufacturer’s protocol. The sequences
for the CTGF primer (GenBank No. NM_001901) were
as follows: forward, 5’-CCTGTGCAGCATGGACGTT-
3’; reverse, 5’-GGACCAGGCAGTTGGCTCTAA-3’,a n d
the sequences for the GAPDH primer were as published
elsewhere [15]. The oligonucleotides were synthesized
by Takara Bio Co. Ltd. (Japan)
Western blotting
Whole cell lysates were extracted from the cultured cells
using standard lysis buffer (20 mM Tris-HCl, 250 mM
NaCl, 1% NP-40, 1 mM dithiothreitol, 10 mM NaF, 2
mM Na3VO4,1 0m MN a 4P2O7), and Protease Inhibitor
Cocktail (Roche, Mannheim, Germany) and stored at
-30°C until use. Protein concentration was determined
using the Bradford method (Bio-Rad Protein Assay
Reagent; BioRad Laboratories, Hercules, CA). The
lysates were mixed with the loading dye and subjected
to 15% sodium dodecyl sulphate (SDS)-polyacrylamide
gel electrophoresis (PAGE). After transfer to a polyviny-
lidine difluoride membrane, a primary antibody was
added: goat anti-CTGF polyclonal antibody (Catalog No.
sc-14939, Santa Cruz Biotechnology Inc. Santa Cruz,
CA, USA) or anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; Abcam Ltd., Cambridge, UK). The
membrane was then washed and reacted with the corre-
sponding secondary antibody conjugated with horserad-
ish peroxidase. Finally, the signals were visualized using
the extended cavity laser system (GE Healthcare Bio-
sciences KK, Tokyo, Japan). Densitometry of the signal
bands was analysed using ImageJ software http://rsb.
info.nih.gov/ij/. Statistical analyses were performed using
Prism™ software (GraphPad Software Inc., San Diego,
CA). The results are shown as mean ± SD. Student’st
test was used to compare between two groups and a p
value of less than 0.05 was considered significant.
Enzyme-linked immunosorbent assay (ELISA)
CTGF levels in the culture supernatant were measured
in duplicate using the Human CTGF ELISA Kit (Pepro-
tech, Rocky Hill, NJ) according to the manufacturer’s
instructions. According to the manufacturer, the detec-
tion range of CTGF using this kit is 63 to 4000 pg/ml.
The results were analyzed using Student’s t-test.
Results
PGE2 downregulates CTGF expression in chondrocytes
Figure 1 shows the results of quantitative PCR. IL-1b
and, to a lesser extent, PGE2 significantly suppressed the
expression of CTGF mRNA. We observed a similar
effect of PGE2 in chondrocyte samples from patients
with traumatic fracture and rheumatoid arthritis (data
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mRNA expression tended to be more potent 4 h after
stimulation than at 24 h after stimulation (Figure 2),
suggesting that suppression occurred at the transcrip-
tional level. A comparison of the effect of EP agonists
and the effect of PGE2 indicated that the effects of buta-
prost (EP2 agonist) and PGE1 alcohol (EP2/EP4 agonist)
were similar to those of PGE2. Sulprostone (EP1/EP3
agonist), however, did not have a suppressive effect.
These findings suggest that EP2 and/or EP4 receptors
are involved in the suppression of CTGF expression by
PGE2 (Figures 1). Based on previous reports that buta-
prost might exert agonistic effects on EP4 at micromolar
concentrations in some cells [16], we further analysed
the effect of PGE2 using EP2/EP4-specific antagonists.
An EP4-specific agonist was not commercially available.
Chondrocytes were stimulated with PGE2 in the pre-
sence or absence of AH6809 (EP2 antagonist) or
GW627368X (EP4 antagonist). The results of quantita-
tive PCR using these antagonists revealed that
GW627368X, but not AH6809, blocked the suppressive
effect of PGE2 on CTGF expression (Figure 3), suggest-
ing that the EP4 receptor has a dominant role in the
effects of PGE2 on CTGF. Western blot analyses pro-
duced similar results (Figure 4), confirming that the
effects of PGE2 were mediated through the EP4 receptor
at the protein level. Of note, in the Western blot, CTGF
protein was detected as several bands of approximately
30 and 35 kD (Figure 4, top). This finding suggests the
presence of cleaved fragments, as reported in previous
studies [5,8,17].
Suppression of CTGF secretion by PGE2
We measured secreted levels of CTGF from cultured
OA chondrocytes byELISA. Basal CTGF levels were
detected in the culture supernatant of three of five OA
Figure 1 Quantitative PCR for CTGF expression in PGE2-o rE P
receptor agonist-stimulated human chondrocytes. Chondrocyte
samples (n = 5, in duplicate) were either stimulated or not
stimulated with PGE2 (10 nM), butaprost (10 μM), PGE1 alcohol (10
nM), sulprostone (1 μM), or IL-1b (10 ng/ml) for 24 h in vitro. The
relative expression of CTGF mRNA was calculated against values of
the internal control GAPDH.
Figure 2 Quantitative PCR for CTGF expression in
chondrocytes: different time points. Chondrocyte samples (n = 3,
a different panel from Figure 1) were stimulated with PGE2 (10 nM)
for 4 or 24 h, and each sample was analysed for the CTGF mRNA as
in Fig. 1.
Figure 3 CTGF mRNA expression in PGE2-stimulated
chondrocytes: blocking experiments. Chondrocyte samples (n =
5, in duplicate) were either stimulated by PGE2 (10 nM) or not for
24 h, with or without pretreatment with an EP-specific antagonist
(AH: AH6809, 10 ng/ml; GW: GW627368X, 5 μM), for 1 h in vitro. The
relative expression of CTGF/CCN2 mRNA was calculated against
values of the internal control, GAPDH using quantitative PCR.
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to the cells significantly decreased CTGF secretion (Fig-
ure 5). As a result, preincubation with AH6809 did not
significantly prevent the decrease in CTGF secretion,
whereas GW267368X abolished the suppressive effect of
PGE2 (Figure 5).
Discussion and Conclusions
CTGF/CCN2 is currently attracting attention for its pos-
sible contribution to chondrocyte metabolism, including
chondrogenesis, chondrocyte proliferation, and extracel-
lular matrix production [4]. Although CTGF is
expressed in human OA chondrocytes as well as in nor-
mal human chondrocytes [6,7], the regulatory mechan-
isms of its expression are not fully understood. Here, we
evaluated whether the catabolic mediator PGE2 is
involved in the regulation of CTGF expression in articu-
lar chondrocytes. Both PGE2 and IL-1b suppressed
CTGF expression in human articular chondrocytes, and
t h ei n h i b i t o r ye f f e c to fP G E 2 was EP4 receptor-
dependent.
PGE2 exerts its effects through the family of EP recep-
tors, i.e., EP1, EP2, EP3, and EP4. Each EP receptor has
a distinct distribution pattern and shows different
responses after PGE2 stimulation (reviewed in [18]). EP2
and EP4 receptors are suggested to deliver important
signals to chondrocytes [19-21]. In this regard, Aoyama
et al. previously reported the dominant expression of
EP2 receptors in human articular cartilage and cultured
chondrocytes, whereas significant expression of EP1 and
EP4 receptors was not detected [20]. Otsuka and
Aoyama et al. also reported that selective stimulation of
the EP2 receptor promoted cartilage regeneration in an
animal model with chondral defects [22], suggesting that
EP2 has a dominant role in chondrocyte proliferation
and cartilage regeneration. Attur et al. [13], however,
recently demonstrated that all four EP receptors (EP1-
EP4) are expressed in both OA and normal cartilage
and in chondrocytes, and that the catabolic effects of
PGE2 are mediated by signaling through EP4 receptors
in OA cartilage. Specifically, the authors demonstrated
that PGE2-induced matrix metalloproteinase production
and type II collagen degradation were both EP4-depen-
dent [13]. In addition, Li et al. demonstrated the predo-
minant expression of EP2 and EP4 receptors in human
articular cartilage, and showed that PGE2 works as a
potent anti-anabolic factor via the suppression of pro-
teoglycan production, which suggests a potential thera-
peutic application of EP2 and EP4 receptor antagonists
[21]. Our results are consistent with their findings in
regard to the implication of the involvement of EP4
receptors in the catabolic response to PGE2 in chondro-
cytes. Specifically, CTGF mRNA and protein expression
was suppressed by an EP4-selective antagonist. Thus,
regulation of the EP4-mediated signal might be an
important target to suppress the degradation process of
inflamedarticular cartilage. Of note, Li et al. also
reported that the expression levels of each EP receptor
Figure 4 CTGF expression in PGE2-stimulated chondrocytes:
Western blot. Top: Chondrocyte samples (n = 5) were either
stimulated by PGE2 (10 nM) or not for 24 h, with or without
pretreatment with an EP-specific antagonist (AH: AH6809, 10 ng/ml;
GW: GW627368X, 5 μM), for 1 h in vitro. Bottom: The relative value
of band intensity (CTGF/GAPDH) was calculated using an image
analyzer.
Figure 5 Secreted levels of CTGF from chondrocytes. The results
of ELISA assays using culture supernatants from OA chondrocytes (n
= 5) are summarized. All of the assays were performed in duplicate.
Masuko et al. BMC Research Notes 2010, 3:5
http://www.biomedcentral.com/1756-0500/3/5
Page 4 of 6might vary between knee and ankle joints [21]. In the
present study, we used 15 knee samples and 2 hip joints
w i t h o u ta n ys i g n i f i c a n td i f f e r e n c ei nt h eC T G F
responses; however, further studies should be performed
to clarify whether chondrocytes in various joints
respond differently to PGE2.
CTGF has several potential functions in chondrocytes.
During chondrogenesis, CTGF has an important role as
a regulator of matrix remodeling and chondrocyte dif-
ferentiation [3,23,24]. Woods et al. recently demon-
strated that CTGF expression in chondrocytes is
regulated by a small GTPase Rac1 and actin organiza-
tion via the Smad binding site in the CTGF promotor
gene, suggesting the involvement of TGF-b/smad signal-
i n gi nC T G Fe x p r e s s i o n[ 2 5 ] .O nt h eo t h e rh a n d ,u s i n g
rabbit auricular (not articular) cartilage, Fujisawa et al.
reported that CTGF might increase proteoglycan synth-
esis and the expression of elastin and type II collagen,
whereas it suppresses apoptotic cell death [26]. Another
recent paper by Maeda et al. reported that CTGF inter-
acts with bone morphologic protein 2 and the complex
might regulate the differentiation of chondrocytic cells
[27]. Further, Nishida et al. recently demonstrated that
CTGF regulates the expression of vascular endothelial
growth factor in chondrocytic cells under hypoxic con-
ditions [28]. Based on these findings, the authors sug-
gested a role for CTGF as a “signal conductor” in
chondrocytes during endochondral ossification [27,28].
Nevertheless, how CTGF suppression by IL-1 and PGE2
modifies the pathophysiology of OA remains unclear.
Considering that CTGF might regulate extracellular
matrix remodeling and is a pro-fibrotic factor [3], it is
possible that CTGF is a downstream factor to inflamma-
tory mediators such as IL-1 and PGE2, which modulate
the balance between synthesis and degradation of the
matrix in the cartilage in inflammatory arthritis.
As for the different bands of CTGF detected in Wes-
tern blot (Figure 4), this finding may indicate the pre-
sence of degradation products and/or posttranscriptional
modification by, for example, glycosylation of CTGF
expressed in chondrocytes. The existence of similar frag-
ments/byproducts has been reported in previous studies
[5]: for example, Yang et al. reported that endogenous
human CTGF is a secreted and glycosylated protein of
approximately 32 to 38 kDa with 208 kDa of N-linked
s u g a r sa n da3 0 - k Dc o r e[ 8 ] .Y a n ge ta l .a l s od e m o n -
strated the presence of differentially degraded forms of
CTGF (18 kDa and 24 kDa) in biological fluids, includ-
ing normal human sera. In addition, Zarrinkalam et al.
demonstrated that CTGF protein is expressed in human
peritoneal mesothelial cells at 36 to 38 kDa and also at
proteolytically processed fragments of lower molecular
weight (23 and 25 kDa) [17]. Western blot analysis in
the present study revealed predominant bands at
a p p r o x i m a t e l y3 0t o3 2k D a ,s u g g e s t i n gt h a tC T G Fi s
deglycosylated in chondrocytes. This point should be
further analysed to clarify the cleavage and function of
each CTGF isoform in chondrocytes.
In conclusion, we demonstrated that PGE2 regulates
CTGF expression in chondrocytes at both the mRNA
and protein levels via the EP4 receptor. Further investi-
gation of the role of CTGF and the PGE2 EP4 receptor
in human chondrocytes might provide clues to establish
novel therapeutic strategies against osteoarthritis.
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